Bigfoot Biomedical, a diabetes startup creating insulin delivery through the use of AI and automation has raised $45 million in the initial tranche of Series C equity financing. The financing round was led by Abbott with support from existing investors, including Quadrant Capital Advisors, Senvest Capital, Janus Henderson, and Cormorant Asset Management.
Read more Abbott Inks Deal with Omada Health to Integrate FreeStyle Libre with Omada’s Health Coaching Platform
Proceeds from the financing will support the completion of product development and FDA clearance for the Bigfoot Unity™ Diabetes Management Program, an injection-based digitized insulin dosing platform utilizing a proprietary, connected insulin pen-based system that integrates Abbott’s FreeStyle Libre glucose sensing technology, reports Business Wire.
Submission of Bigfoot Unity is anticipated in 2020 with a target launch by year-end 2020. Series C funds will also be directed toward clinical trials of future generation Bigfoot Unity systems incorporating closed-loop technology for injection users.
Insulin-requiring diabetes impacts over six million Americans, the vast majority of whom are not reaching clinical targets for optimal glucose levels.
Alongside the news of its financing round, Bigfoot also announced the signing of another partnership with Abbott that aims to develop and commercialize diabetes management programs that integrate with the FreeStyle Libre platform.
“We are excited to announce Abbott’s deepening support of Bigfoot Biomedical with this Series C financing,” said Jeffrey Brewer, chief executive officer of Bigfoot Biomedical. “Their investment bolsters and validates our approach to provide a wholly integrated offering, utilizing innovative technologies. Our industry partnership with Abbott uniquely positions us to reduce the heavy burden of dosing decisions for people with insulin-requiring diabetes.”
Read more American Diabetes Association Recognizes Use of Autonomous AI for Diabetes Care
Milpitas, California based Bigfoot is a medical device company dedicated to simplifying and optimizing insulin delivery and dosing decisions for people living with insulin-requiring diabetes through the use of AI and automation. The company’s integrated system and services address many of the challenges facing people with Type 1 and Type 2 diabetes, health care providers, and insurance institutions.